BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586. [PMID: 19491875 DOI: 10.1038/ajg.2009.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5:555-558. [PMID: 22115374 DOI: 10.1016/j.crohns.2011.05.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 7.2] [Reference Citation Analysis]
2 Jang YW, Park YS, Kim SH, Jo YJ, Jo YK, Ahn SB, Seo YS, Hong YO. A Case of Crohn's Disease Having Normal Delivery after Infliximab Treatment during Early Pregnancy. Korean J Gastroenterol 2013;61:37. [DOI: 10.4166/kjg.2013.61.1.37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Crawford NW, Catto-Smith AG, Oliver MR, Cameron DJ, Buttery JP. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol. 2011;11:87. [PMID: 21798078 DOI: 10.1186/1471-230x-11-87] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
4 Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, Mocci G, Pugliese D, De Vitis I, Gasbarrini A. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohns Colitis. 2013;7:113-119. [PMID: 22464811 DOI: 10.1016/j.crohns.2012.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
5 Swoger JM, Regueiro M. Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops: . Inflammatory Bowel Diseases 2014;20:926-35. [DOI: 10.1097/mib.0000000000000002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
6 Mahadevan U, Kane S. Use of infliximab in pregnancy. Am J Gastroenterol 2010;105:219; author reply 219-20. [PMID: 20054309 DOI: 10.1038/ajg.2009.532] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
8 Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review. World J Gastroenterol 2013; 19(44): 7867-7873 [PMID: 24307780 DOI: 10.3748/wjg.v19.i44.7867] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
9 Soldini D, Gaspert A, Montani M, Reineke T, Rogler G, Odze R, Weber A. Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists. J Clin Pathol 2014;67:582-6. [DOI: 10.1136/jclinpath-2014-202199] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
10 Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010;16:916-924. [PMID: 19885908 DOI: 10.1002/ibd.21147] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
11 Miyake Y, Hasebe A, Tanihira T, Shiraishi A, Imai Y, Tatsukawa H, Yamago H, Nakahara H, Shimizu Y, Ninomiya K, Hiraoka A, Miyata H, Ninomiya T, Michitaka K. Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease. Case Reports Hepatol 2013;2013:461879. [PMID: 25374717 DOI: 10.1155/2013/461879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
12 Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598-1619. [PMID: 20198712 DOI: 10.1002/ibd.21219] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 11.1] [Reference Citation Analysis]
13 Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Review of Clinical Immunology 2014;6:659-66. [DOI: 10.1586/eci.10.46] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
14 Bern EM, Bousvaros A. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician’s conundrum. Expert Review of Clinical Immunology 2014;9:117-27. [DOI: 10.1586/eci.12.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Díaz-Couselo FA, Zylberman M. Catheter-Related Acremonium kiliense Fungemia in a Patient with Ulcerative Colitis under Treatment with Infliximab. Case Rep Infect Dis 2011;2011:710740. [PMID: 22567476 DOI: 10.1155/2011/710740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72:2333-2349. [PMID: 23181971 DOI: 10.2165/11638120-000000000-00000] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
17 Kane S. Preparing the Patient for Immunosuppressive Therapy. Curr Gastroenterol Rep 2010;12:502-6. [DOI: 10.1007/s11894-010-0142-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
18 Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72:2333-2349. [PMID: 23181971 DOI: 10.165/11638120-000000000-00000] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Fei BY, Lv HX, Zheng WH. Fluorescent quantitative PCR of Mycobacterium tuberculosis for differentiating intestinal tuberculosis from Crohn's disease. Braz J Med Biol Res. 2014;47:166-170. [PMID: 24519133 DOI: 10.1590/1414-431x20133277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
20 Papa A, Gasbarrini A. Response to El-Matary. Am J Gastroenterol 2009;104:2852-3. [DOI: 10.1038/ajg.2009.477] [Reference Citation Analysis]
21 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
22 Gopal K, Min AD. Chemoprevention of Patients with Hepatitis B Receiving Chemotherapy or Bone Marrow Transplant. Curr Hepatitis Rep 2010;9:178-86. [DOI: 10.1007/s11901-010-0048-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, Armuzzi A, Gasbarrini A, Papa A. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int J Mol Sci 2018;19:E2199. [PMID: 30060508 DOI: 10.3390/ijms19082199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
24 van der Woude CJ, Kolacek S, Dotan I, Øresland T, Vermeire S, Munkholm P, Mahadevan U, Mackillop L, Dignass A; for the European Crohn's Colitis Organisation (ECCO). European evidenced-based consensus on reproduction in inflammatory bowel disease. Journal of Crohn's and Colitis 2010;4:493-510. [DOI: 10.1016/j.crohns.2010.07.004] [Cited by in Crossref: 113] [Cited by in F6Publishing: 96] [Article Influence: 9.4] [Reference Citation Analysis]
25 Jin T, Fei B, Zhang Y, He X. The diagnostic value of polymerase chain reaction for Mycobacterium tuberculosis to distinguish intestinal tuberculosis from crohn's disease: A meta-analysis. Saudi J Gastroenterol. 2017;23:3-10. [PMID: 28139494 DOI: 10.4103/1319-3767.199135] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
26 Sato T. Tumor necrosis factor-α blockade and development of uveal melanoma: expected adverse effect or just coincidence? Mayo Clin Proc 2014;89:1467-70. [PMID: 25444483 DOI: 10.1016/j.mayocp.2014.09.005] [Reference Citation Analysis]